Canbex Therapeutics Ltd to Present at Biotech Showcase™ 2014

| Print |
Monday, 13 January 2014 10:00 (UTC + 1)

Canbex logo

London, UK, January 13, 2014 / B3C newswire / – Canbex Therapeutics Ltd announced today that Dr Jesse Schulman, Chief Executive Officer of Canbex, will be presenting at the Biotech Showcase™ 2014 Conference being held in San Francisco, CA.

Details of Canbex Therapeutic Ltd’s presentation are as follows:

Event: Biotech Showcase™ 2014 Conference
Date: Tuesday January 14th, 2014
Time: 9.30am
Location:       
B-Mission I (4th Floor) Parc 55 Wyndham San Francisco Union Square Hotel

 
The presentation will outline recent progress of its novel, orally active lead compound aimed at changing the treatment of spasticity in patients with multiple sclerosis through improved tolerability.

Canbex reports that its Phase I clinical trial of lead compound VSN16R is progressing well and according to plan. “The superior tolerability of VSN16R is supported by our clinical results to date,” commented Canbex CEO Dr Jesse Schulman. “In addition, the pharmacokinetic data suggest that a patient-friendly dosing regime can be achieved, which would also be a significant advantage.”

Canbex’s Phase I trial to study the safety, tolerability and pharmacokinetics of VSN16R is being conducted by Quintiles, the world’s largest clinical research organization, and will enrol up to 72 subjects.

Dr Keith Powell, Chairman of Canbex, said: “Canbex is delighted that it was selected to present the VSN16R story at the Biotech Showcase, a leading event for the life sciences industry and investors. We believe that VSN16R offers a commercial and investment opportunity with life-changing potential for people with multiple sclerosis.”

“With good safety and tolerability results so far, Canbex and its world-leading clinical advisors are preparing for a Phase II clinical trial to study the compound’s efficacy,” Dr Powell added.

Canbex believes that VSN16R has the potential to become an important advance in the treatment of spasticity, a condition for which there remains a substantial unmet medical need. Spasticity is characterized by sudden and uncontrollable movements of limb and torso musculature, and is among the most painful, damaging and debilitating symptoms of multiple sclerosis. Current drug treatments have a high level of undesirable side effects, particularly sedation and cognitive dysfunction. Many patients cannot tolerate current treatments, and so are treated with palliative measures alone, or with drug regimes that result in poor quality of life.

Canbex closed a Series A funding round in April 2013 that was led by Merck Serono Ventures, and the company won a Biocatalyst grant from the UK government’s Technology Strategy Board in March 2013. Other investors in Canbex include the Wellcome Trust, the US National Multiple Sclerosis Society, University College London (UCL Business Ltd) and Esperante Ventures.


About Canbex
Canbex is a single-asset company that was established for the purpose of developing the VSN compound series. In addition to its pioneering scientific founders and clinical advisors, Canbex has assembled a skilled and focused management team. Development activities are carried out through leading CROs and CMOs. The company’s capital efficiency and lean management strategy ensure that funds are deployed overwhelmingly to compound development and that the company is well structured for exit.

Meet Canbex at:

Biotech Showcase, San Francisco, CA, USA, 13 - 15 January 2014

To contact Canbex, please email us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it